Tandutinib-MLN518-DataSheet-生命科學(xué)試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemETandutinibCat. No.: HY-10202CAS No.: 387867-13-2Synonyms: MLN518; CT53518分式: CHNO分量: 562.7作靶點: FLT3作通路: Protein Tyrosine Kinase/RTK儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 36 mg/mL (

2、63.98 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 1.7771 mL 8.8857 mL 17.7715 mL5 mM 0.3554 mL 1.7771 mL 3.5543 mL10 mM 0.1777 mL 0.8886 mL 1.7771 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。體內(nèi)實驗 Tandutinib is prepared in PBS4.BIOLOGICAL ACTIVITY物活

3、性 Tandutinib（MLN518, CT53518）是FLT3拮抗劑，IC50為0.22 M，還抑制PDGFR 和c-Kit。1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemE戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Sci Transl Med. 2018 Jul 18;10(450). pii: eaaq1093. Drug Des Devel Ther. 2018 Apr 30;12:1009-1017. Biochem Biophys Res Commun. 2017 Aug 19;490(2):209-216.See more customer v

4、alidations on HYPERLINK / www.MedChemEREFERENCES1. Kelly LM, et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell, 2002,1(5), 421-432.2. Griswold IJ, et al. Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hemat

5、opoiesis. Blood, 2004, 104(9), 2912-2918.3. Schittenhelm MM, et al. The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabineand daunorubicin. Cell Cycle, 2009, 8(16), 2621-2630.4. Salama Y, et al. The angiogenic factor Egfl7 alters thymogenesis by activating Flt3 signaling. Biochem Biophys Res Commun. 2017 Aug19;490(2):209-216.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792;